Literature DB >> 33058488

2018 American Heart Association redefinition of resistant hypertension: Major adverse cardiovascular and renal events.

Robert M Carey1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33058488      PMCID： PMC8030046          DOI： 10.1111/jch.14042

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  10 in total

1.  Prevalence of Apparent Treatment-Resistant Hypertension in the United States.

Authors:  Robert M Carey; Swati Sakhuja; David A Calhoun; Paul K Whelton; Paul Muntner
Journal:  Hypertension       Date:  2019-02       Impact factor: 10.190

Review 2.  Report of the National Heart, Lung, and Blood Institute Working Group on Hypertension: Barriers to Translation.

Authors:  Curt D Sigmund; Robert M Carey; Lawrence J Appel; Donna K Arnett; Hayden B Bosworth; William C Cushman; Zorina S Galis; Melissa Green Parker; John E Hall; David G Harrison; Alicia A McDonough; Holly L Nicastro; Suzanne Oparil; John W Osborn; Mohan K Raizada; Jacqueline D Wright; Young S Oh
Journal:  Hypertension       Date:  2020-02-17       Impact factor: 10.190

3.  Outcome-Driven Thresholds for Ambulatory Blood Pressure Based on the New American College of Cardiology/American Heart Association Classification of Hypertension.

Authors:  Yi-Bang Cheng; Lutgarde Thijs; Zhen-Yu Zhang; Masahiro Kikuya; Wen-Yi Yang; Jesus D Melgarejo; José Boggia; Fang-Fei Wei; Tine W Hansen; Cai-Guo Yu; Kei Asayama; Takayoshi Ohkubo; Eamon Dolan; Katarzyna Stolarz-Skrzypek; Sofia Malyutina; Edoardo Casiglia; Lars Lind; Jan Filipovský; Gladys E Maestre; Yutaka Imai; Kalina Kawecka-Jaszcz; Edgardo Sandoya; Krzysztof Narkiewicz; Yan Li; Eoin O'Brien; Ji-Guang Wang; Jan A Staessen
Journal:  Hypertension       Date:  2019-08-05       Impact factor: 10.190

4.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

5.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

6.  Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research.

Authors:  David A Calhoun; Daniel Jones; Stephen Textor; David C Goff; Timothy P Murphy; Robert D Toto; Anthony White; William C Cushman; William White; Domenic Sica; Keith Ferdinand; Thomas D Giles; Bonita Falkner; Robert M Carey
Journal:  Hypertension       Date:  2008-04-07       Impact factor: 10.190

Review 7.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 9.897

8.  Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudies.

Authors:  Bryan Williams; Thomas M MacDonald; Steve V Morant; David J Webb; Peter Sever; Gordon T McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Sandosh Padmanabhan; Isla S Mackenzie; Jackie Salsbury; Morris J Brown
Journal:  Lancet Diabetes Endocrinol       Date:  2018-04-11       Impact factor: 32.069

9.  Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment-resistant hypertension in high-risk hypertension patients.

Authors:  Kyeong-Hyeon Chun; Chan Joo Lee; Jaewon Oh; Sang-Hak Lee; Seok-Min Kang; Kazuomi Kario; Sungha Park
Journal:  J Clin Hypertens (Greenwich)       Date:  2020-09-20       Impact factor: 3.738

10.  Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.

Authors:  Bryan Williams; Thomas M MacDonald; Steve Morant; David J Webb; Peter Sever; Gordon McInnes; Ian Ford; J Kennedy Cruickshank; Mark J Caulfield; Jackie Salsbury; Isla Mackenzie; Sandosh Padmanabhan; Morris J Brown
Journal:  Lancet       Date:  2015-09-20       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.